Skip to main content

Table 1 Comparison of clinical information and serum liver function indices of 185 patients with CHB

From: Expression changes of Tim-3 as one of supplementary indicators for monitoring prognosis of liver pathological changes in chronic HBV infection

Index

Baseline level (95% CI)

12-Months follow-up (95%CI)

TP, g/L

77.83 ± 5.97 (76.94–78.69)

77.82 ± 7.56 (76.70–78.92)

ALB, g/L

49.10 ± 4.38 (48.46–49.74)

52.46 ± 32.27 (47.76–57.23)

GLB, g/L

28.73 ± 4.48 (28.06–29.36)

27.71 ± 4.21*(27.07–28.31)

A/G

1.75 ± 0.31 (1.71–1.80)

1.93 ± 1.36**(1.74–2.14)

ALT, U/L

50.75 ± 76.07 (39.83–62.13)

25.32 ± 25.32**(21.69–29.11)

AST, U/L

47.53 ± 65.94 (38.00–57.34)

26.25 ± 14.62**(24.18–28.46)

ALP, U/L

86.44 ± 32.42 (82.08–91.53)

80.85 ± 27.03(77.23–85.11)

ChE, U/L

8540.39 ± 2189.15 (8221.87–8863.37)

8898.41 ± 2102.60 (8584.14–9199.52)

TBA, μmol/L

20.49 ± 30.77 (16.09–25.11)

15.71 ± 21.99*(12.61–19.05)

TBIL, μmol/L

9.05 ± 8.12 (7.85–10.23)

8.45 ± 4.37(7.84–9.12)

DBIL, μmol/L

4.12 ± 5.82 (3.28–4.99)

3.50 ± 1.87(3.25–3.79)

IDBIL, μmol/L

4.93 ± 4.37 (4.26–5.54)

4.95 ± 3.42(4.46–5.46)

γ-GT, U/L

41.52 ± 41.73 (35.60–47.82)

27.11 ± 25.18**(23.49–30.86)

GPDA, U/L

100.67 ± 27.49 (96.78–104.81)

93.81 ± 21.52*(90.84–97.09)

AFP, ng/mL

7.63 ± 16.87 (5.20–10.13)

3.93 ± 7.94**(2.78–5.11)

HBsAg, IU/mL

14,194.86 ± 24,143.84 (10,711.40–17,771.29)

7521.35 ± 16,629.74**(5107.19–9982.06)

anti-HBs, mIU/mL

1.41 ± 9.62 (0.02–2.84)

0.90 ± 4.22(0.29–1.53)

anti-HBc, S/CO

8.54 ± 1.25 (8.35–8.71)

8.25 ± 1.25**(8.06–8.43)

HBeAg, PEIU/mL

304.51 ± 547.03 (227.74–387.92)

151.52 ± 412.97*(92.54–213.59)

anti-HBe, S/CO

10.39 ± 17.32 (7.90–12.98)

5.26 ± 12.46(3.49–7.14)

HBV-DNA, IU/mL

2.91E8 ± 8.31E8 (1.68E8-4.11E8)

1.62E7 ± 8.25E7**(4.25E6-2.85E7)

Tim3, pg/mL

879.23 ± 646.15 (787.90–977.09)

655.98 ± 399.33**(600.65–717.37)

Inflammation grading

1.61 ± 0.75 (1.50–1.72)

1.38 ± 0.55**(1.30–1.46)

Fibrosis stage

1.31 ± 1.07 (1.16–1.47)

1.34 ± 0.95 (1.20–1.48)

  1. CI confidence interval
  2. *P < 0.05 versus the baseline level; **P < 0.01, versus the baseline level